While GPC3- and telomerase-based vaccines have not provided meaningful clinical results, tumor unique peptide identification through HLA-peptidomics is the more robust and personalized approach for anti-HCC vaccine treatment [283,284]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.